Investment Summary |
|
---|---|
Date | 2008-12-12 |
Target | Evogen |
Sector | Technology Hardware |
Investor(s) | L Capital Partners |
Deal Type | Venture |
Deal Value | 3M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Private Equity Firm |
---|---|
Founded | 2004 |
PE ASSETS | 165M USD |
Size | Small |
Type | Sector Focused |
L Capital Partners is a specialist private equity firm focused on investing in companies operating within the healthcare, technology, and energy/environmental sectors, looking to bring 'groundbreaking products to market'. Within healthcare, L Capital looks to invest in biopharmaceutical and medical device businesses. Within technology, the Firm's emphasis is on security/defense and IT businesses. And within the energy/environmental sector, the L Capital's focus is investing in opportunities that 'improve the quality of life'. L Capital was formed in 2004 and has offices in New York City and Tel Aviv, Israel.
DEAL STATS | # |
---|---|
Overall | 13 of 16 |
Sector (Technology Hardware) | 1 of 1 |
Type (Venture) | 12 of 14 |
State (Missouri) | 1 of 1 |
Country (United States) | 13 of 15 |
Year (2008) | 4 of 4 |
Size (of disclosed) | 4 of 4 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2008-10-17 |
CeNeRx BioPharma
Cary, North Carolina, United States CeNeRx is a privately held clinical-stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for treatment resistant depression. RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profile. The company's CNS pipeline also includes clinical-stage hypothalamic-pituitary adrenal (HPA) axis modulators for the treatment of a variety of CNS disorders including anxiety and depression; a small molecule, orally active agent for the prevention and treatment of neuropathies and neurodegenerative disorders; and a series of selective cannabinoid compounds that have successfully completed preclinical proof-of-concept studies for the treatment of pain, glaucoma and spasticity. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2009-03-01 |
WiSpry
Irvine, California, United States WiSpry, Inc. is a fabless RF semiconductor company that develops RF silicon integrated circuits and components for wireless communication products. |
Buy | - |